Drug Profile

Adenovirus-specific T cell therapy - Kuur Therapeutics

Alternative Names: ADV-specific T cell therapy - Kurr Therapeutics; Cytovir ADV

Latest Information Update: 11 May 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cell Medica
Developer Kuur Therapeutics
Class Cell therapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Adenovirus infections

Most Recent Events

04 May 2021 Kuur Therapeutics has been acquired by Athenex
10 Mar 2020 Cell Medica is now called Kuur Therapeutics
07 Aug 2018 Efficacy and adverse events data from a phase I/II ASPIRE trial in Adenovirus infections released by Cell Medica

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com